|1.01 -0.02 (-1.94%)||12-07 16:00|
|Targets||6-month :||1.3||1-year :||1.53|
|Resists||First :||1.11||Second :||1.3|
|Supports||First :||0.81||Second :||0.67|
|MAs||MA(5) :||1.05||MA(20) :||0.99|
|MA(100) :||1.32||MA(250) :||1.75|
|MACD||MACD :||-0.1||Signal :||-0.1|
|%K %D||K(14,3) :||36.1||D(3) :||43|
|52-week||High :||4.13||Low :||0.81|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SLS ] has closed above bottom band by 42.6%. Bollinger Bands are 43.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||1.07 - 1.08||1.08 - 1.08|
|Low:||0.99 - 0.99||0.99 - 1|
|Close:||1 - 1.01||1.01 - 1.02|
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||32 (M)|
|Shares Float||32 (M)|
|Held by Insiders||0.2 (%)|
|Held by Institutions||18 (%)|
|Shares Short||4,580 (K)|
|Shares Short P.Month||2,040 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||-0.15|
|Profit Margin||0 %|
|Operating Margin||0 %|
|Return on Assets (ttm)||-143.6 %|
|Return on Equity (ttm)||-874 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0.02|
|Sales Per Share||0|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-32 (M)|
|Levered Free Cash Flow||-29 (M)|
|Price to Book value||-7.22|
|Price to Sales||0|
|Price to Cash Flow||-1.03|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|